U.S. FDA Says Agency Hasn’t Approved Ranbaxy’s Generic Lipitor

The Food and Drug Administration hasn’t approved Ranbaxy Laboratories Ltd.’s generic version of Pfizer Inc.’s $10.7 billion Lipitor cholesterol pill, Sandy Walsh, a spokeswoman for the agency, said.

An FDA vendor made a mistake and a statement from the agency announcing the approval of Ranbaxy’s generic drug was distributed in error, Walsh said in an e-mail.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE